Non-Small Cell Lung Cancer (NSCLC) in Young Adults, Age < 50, Is Associated with Late Stage at Presentation and a Very Poor Prognosis in Patients That Do Not Have a Targeted Therapy Option: A Real-World StudyD.J. Hughes, Alexandros Georgiou, Benjamin A. Taylor et al.|Cancers|2022Cited by 22
PD-L1 imaging with [99mTc]NM-01 SPECT/CT is associated with metabolic response to pembrolizumab with/without chemotherapy in advanced lung cancerD.J. Hughes, Gary Cook, Gitasha Chand et al.|British Journal of Cancer|2025Cited by 4
Clinical predictors of long-term efficacy of first-line pembrolizumab monotherapy in non-small cell lung cancer (NSCLC): an interim analysis of real-world dataHelen-Cara Younan, Debra H. Josephs, Shuai Zhang et al.|Lung Cancer|2022Cited by 0